Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 22;20(10):1304–1313. doi: 10.1080/15384047.2019.1632637

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 2. — UNC-45A expression levels across cell types and its fractionation with MTs in mammalian cells. a. Western blot analysis for levels of UNC-45A in the indicated cell lines. c. Quantification of UNC-45A expression levels expressed as UNC-45A/total protein ratio. c. MTs from SKOV-3 cell lines in presence or in absence (mock) of 1 μM taxol for 1 h prior ultracentrifugation. Supernatant and pellet fractions were fractionated by SDS-PAGE and subjected to Western blot analysis using anti-UNC-45A and anti-α-tubulin, antibodies. d. Quantification of % of tubulin and UNC-45A in each fraction following mock treatment. e. Quantification of % of tubulin and UNC-45A in each fraction following taxol treatment. Overall, taxol treatment resulted in an approximately fivefold increase in the amounts of tubulin and of UNC-45A found in the pellet versus mock. f. Actin and myosin II from SKOV-3 cell lines in presence or in absence (mock) of 1μM taxol for 1-h prior ultracentrifugation. Supernatant and pellet fractions were fractionated by SDS-PAGE and subjected to Western blot analysis using anti-actin and anti-myosin II antibodies. Asterisk indicates an aspecific band using a monoclonal antibody against myosin II LC. g. Quantification of % of actin and myosin II in each fraction following mock treatment. H. Quantification of % of actin and myosin II in each fraction following taxol treatment. Overall, taxol treatment resulted in a slight increase (25% after adjusting for total protein loading, which is slightly higher in the bottom last lane of Figure 2F) of actin and no increase in the amount of myosin II in the pellet fractions as compared to mock treatment.